Claims for Patent: 7,232,572

Summary for Patent: 7,232,572

Title:	Methods of treating rosacea
Abstract:	A method of treating rosacea in a human in need thereof comprising administering to said human a tetracycline compound in an amount that is effective to treat rosacea, but has substantially no antibiotic activity.
Inventor(s):	Ashley; Robert A. (Tucson, AZ)
Assignee:	CollaGenex Pharmaceuticals, Inc. (Newtown, PA)
Application Number:	11/061,866
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,232,572
Patent Claims:	1. A method for treating papules and pustules of rosacea in a human in need thereof comprising administering orally to said human a tetracycline compound, or a pharmaceutically acceptable salt thereof, in an amount that is effective to treat the papules and pustules of rosacea, but has substantially no antibiotic activity, said amount being 10-80% of the antibiotic amount, wherein the tetracycline compound is an antibiotic tetracycline compound or a pharmaceutically acceptable salt thereof administered in an amount that results in no reduction of skin microflora during a six-month treatment, without administering a bisphosphonate compound. 2. A method according to claim 1, wherein said tetracycline compound is minocycline or a pharmaceutically acceptable salt thereof administered in an amount which results in a serum concentration of 0.8 .mu.g/ml. 3. A method according to claim 1, wherein said tetracycline compound is tetracycline or a pharmaceutically acceptable salt thereof administered in an amount which results in a serum concentration of 0.5 .mu.g/ml. 4. A method according to claim 1, wherein said tetracycline compound is an antibiotic tetracycline compound or a pharmaceutically acceptable salt thereof administered in an amount which results in a serum concentration which is 10-80% of the minimum antibiotic serum concentration. 5. A method according to claim 4, wherein said antibiotic tetracycline compound is doxycycline, minocycline, tetracycline, oxytetracycline, chlortetracycline, demeclocycline or pharmaceutically acceptable salts of any such compound. 6. A method according to claim 5, wherein said antibiotic tetracycline compound is doxycycline or a pharmaceutically acceptable salt thereof. 7. A method according to claim 6, wherein said doxycycline or pharmaceutically acceptable salt thereof is administered in an amount which provides a serum concentration in the range of about 0.1 to about 0.8 .mu.g/ml. 8. A method according to claim 6, wherein said doxycycline or pharmaceutically acceptable salt thereof is administered in an amount of 20 milligrams twice daily. 9. A method according to claim 7, wherein said doxycycline or pharmaceutically acceptable salt thereof is administered by sustained release. 10. A method according to claim 9, wherein said doxycycline or pharmaceutically acceptable salt thereof is administered in an amount of 40 milligrams. 11. A method according to claim 1, wherein said tetracycline compound is an antibiotic tetracycline compound or a pharmaceutically acceptable salt thereof administered in an amount which is 10-70% of the antibiotic amount. 12. A method according to claim 1, wherein said tetracycline compound is doxycycline or a pharmaceutically acceptable salt thereof. 13. A method according to claim 12, wherein said doxycycline is doxycycline monohydrate. 14. A method according to claim 12, wherein said doxycycline or pharmaceutically acceptable salt thereof is administered in an amount of 40 milligrams. 15. A method according to claim 14, wherein said doxycycline or pharmaceutically acceptable salt thereof is administered by sustained release. 16. A method according to claim 12, wherein said doxycycline or pharmaceutically acceptable salt thereof is administered twice a day in a dose of 20 mg. 17. A method according to claim 1, wherein said tetracycline compound is minocycline, tetracycline, oxytetracycline, chlortetracycline, demeclocycline or pharmaceutically acceptable salts of any such compound. 18. A method according to claim 4, wherein said tetracycline compound is doxycycline or a pharmaceutically acceptable salt thereof administered in an amount which results in a serum concentration of approximately 1.0 .mu.g/ml. 19. A method according to claim 4, wherein said tetracycline compound is minocycline, tetracycline, oxytetracycline, chlortetracycline, demeclocycline or pharmaceutically acceptable salts of any such compound. 20. A method for treating papules and pustules of rosacea in a human in need thereof comprising administering orally to said human a hydrate of doxycycline in an amount that is effective to treat the papules and pustules of rosacea, but has substantially no antibiotic activity, said amount being 10-80% of the antibiotic amount, wherein the hydrate of doxycycline is administered in an amount that results in no reduction of skin microflora during a six-month treatment, said method not comprising administering a bisphosphonate compound. 21. A method according to claim 20, wherein said hydrate of doxycycline is doxycycline monohydrate. 22. A method according to claim 20 wherein said hydrate of doxycycline is administered in an amount which is 10-70% of the antibiotic amount. 23. A method according to claim 20, wherein said hydrate of doxycycline is administered in an amount of 40 milligrams. 24. A method according to claim 20, wherein said hydrate of doxycycline is administered by sustained release. 25. A method according to claim 20, wherein said hydrate of doxycycline is administered twice a day in a dose of 20 mg. 26. A method according to claim 23, wherein said hydrate of doxycycline is administered once a day.